Company news
Humanwell Healthcare (Group) Co.,Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(600079)"Humanwell Healthcare (Group) Co., Ltd."Report for Q3 2026
October 29, 2026
(600079)"Humanwell Healthcare (Group) Co., Ltd."Announcement on Resolutions of the 13th Meeting of the 11th Board of Directors
October 29, 2026
(600079)"Humanwell Healthcare (Group) Co., Ltd."Announcement on Conducting Foreign Exchange Derivatives Trading Business
October 29, 2026
(600079)"Humanwell Healthcare (Group) Co., Ltd."Announcement on Obtaining the U.S. FDA Approval Number for Lubiprostone Soft Capsules
October 19, 2026
(600079)"Humanwell Healthcare (Group) Co., Ltd."Announcement on Obtaining the Marketing Authorization for Sugammadex Sodium Injection from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)
October 13, 2026
(600079)"Humanwell Healthcare (Group) Co., Ltd."Announcement on Obtaining the US FDA Approval Number for Diltiazem Hydrochloride Tablets
October 8, 2026
(600079)"Humanwell Healthcare (Group) Co., Ltd."Indicative Announcement on Disclosure of Proposal for 2026 Private Placement of A-Shares (Second Revised Draft)
September 29, 2026
(600079)"Humanwell Healthcare (Group) Co., Ltd."Announcement on the Dilution of Immediate Returns, Measures to Mitigate Such Dilution and the Undertakings by Relevant Parties in Relation to the Private Placement of A-Shares (Second Revised Draft)
September 29, 2026
(600079)"Humanwell Healthcare (Group) Co., Ltd."Announcement on Signing Supplemental Agreement (II) to the Conditional Share Subscription Agreement for the Private Placement of Shares with the Controlling Shareholder and Related Party Transaction
September 29, 2026
(600079)"Humanwell Healthcare (Group) Co., Ltd."Announcement on Resolutions of the 12th Meeting of the 11th Board of Directors
September 29, 2026
(600079)"Humanwell Healthcare (Group) Co., Ltd."Announcement on Adjustments to the Plan for Private Placement of Shares
September 29, 2026
Announcement on Explanation of Revisions to Proposal for 2026 Private Placement of A-Shares (Second Revised Draft) and Relevant Documents
September 29, 2026
Indicative Announcement on the Reply to the Review Inquiry Letter Regarding the Application Documents for the Private Placement of Shares and Updates of the Prospectus and Other Application Documents
September 23, 2026
Announcement on Obtaining Drug Registration Certificate for Phloroglucinol Orally Disintegrating Tablets
September 11, 2026
Announcement on Completion of the Sale of Assets by a Wholly-owned Subsidiary
September 4, 2026
Announcement on the Initiation of Phase II Clinical Trials for RFUS-949 Tablet
September 3, 2026
Indicative Announcement on Acceptance of Application of the Subsidiary for Drug Marketing Authorization
August 31, 2026
Announcement on Convening the 2026 Semi-annual Performance Briefing
August 26, 2026
Announcement on Resolutions of the 11th Meeting of the 11th Board of Directors
August 25, 2026
Announcement on the Initiation of Phase II Clinical Trials for RFUS-188 Injection
August 20, 2026
Announcement on Obtaining the Notice of Approval for Clinical Trial of Sufentanil Citrate Injection
August 10, 2026
Announcement on Obtaining the Drug Registration Certificate for Brexpiprazole Tablets
August 6, 2026
Announcement on Acceptance by Shanghai Stock Exchange of Application for Private Placement of A Shares
August 4, 2026
Announcement on the Progress of Asset Disposal by Wholly-Owned Subsidiary
July 28, 2026
Announcement on Acquisition of the Drug Registration Certificate for Carbamazepine Sustained-Release Tablets (II)
July 27, 2026
Announcement on Obtaining the Drug Registration Certificate for Vinorelbine Tartrate Soft Capsules
July 24, 2026
Announcement on the Approval of Nintedanib Soft Capsules by the US FDA
July 10, 2026
Announcement on the Initiation of Phase II Clinical Trial for HW211026 Ointment
July 9, 2026
Announcement on Obtaining Notice of Approval for Drug Clinical Trial for Hydromorphone Hydrochloride Tablets
July 6, 2026
Announcement on Attending the 2026 Collective Reception Day for Investors of Listed Companies in Hubei Jurisdiction and 2025 Annual Performance Briefing
June 30, 2026
Announcement on Obtaining Notice of Approval for Drug Clinical Trial of HWS113 for Injection
June 25, 2026
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
June 23, 2026
Announcement on Tapentadol Hydrochloride Oral Solution Obtaining Notice of Approval for Drug Clinical Trial
June 22, 2026
Indicative Announcement on Disclosure of the Plan for Issuing A-shares to Specific Objects in 2026 (Revised Draft)
June 18, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
June 5, 2026
Announcement on Resolutions of the 9th Meeting of the 11th Board of Directors
June 4, 2026
Indicative Announcement on Acceptance of Application for Drug Marketing Authorization of Subsidiary
June 3, 2026
Announcement on Hydrochloride R-Chloroamphetamine Injection Obtaining Notice of Approval for Drug Clinical Trial
May 13, 2026
Announcement on RFUS-188 Injection Obtaining Notice of Approval for Drug Clinical Trial
May 6, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
April 30, 2026
Report for Q1 2026
April 29, 2026
Announcement on Resolutions of the 7th Meeting of the 11th Board of Directors
April 14, 2026
Announcement on Obtaining Marketing Authorization from the German Federal Institute for Drugs and Medical Devices (BfArM) for Remifentanil Hydrochloride for Injection
April 9, 2026
Announcement on Convening the 2025 Annual Performance Briefing
April 8, 2026
Announcement on Obtaining Drug Registration Certificate by Subsidiary
April 7, 2026
Announcement on Risk Assessment Report for China Merchants Group Finance Co., Ltd.
March 30, 2026
Announcement on Initiation of Phase II Clinical Trial for HW091077 Tablets
March 23, 2026
Announcement on Holding Subsidiary's Passing EU GMP Compliance Inspection
March 2, 2026
Announcement on Micafungin Sodium for Injection Obtaining US FDA Approval
February 27, 2026
Announcement on the Temporary Suspension of the Shareholders’ Meeting to Deliberate on the Issuance of A-shares to Specific Investors in 2026
February 24, 2026